October 5, 2017

FDA issues Safety Alert for intraocular TMV injections

By: Judy Mathias
Share

Editor's Note

The Food & Drug Administration (FDA) on October 3 issued a Safety Alert saying the agency had received an adverse event report on a patient who was diagnosed with bilateral hemorrhagic occlusive retinal vasculitis after being administered injections of a compounded triamcinolone, moxifloxacin, vancomycin (TMV) formulation in each eye at the end of cataract surgery procedures that were done 2 weeks apart.

The TMV formulation was compounded by Imprimis Pharmaceuticals (Ledgewood, New Jersey).

Read More >>
Live chat by BoldChat